NCT00186225CompletedNot Applicable
Stem Cell Transplantation From Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY)
Stanford University2 sites in 1 country250 target enrollmentStarted: September 16, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Stanford University
- Enrollment
- 250
- Locations
- 2
- Primary Endpoint
- oxicity and efficacy of TBI and cyclophosphamide as preparation for hematopoietic cell transplantation from partially matched and unrelated donors.
Study Overview
Brief Summary
To evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.
Detailed Description
Stem Cell Transplantation from Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY). To administer high dose radio-chemotherapy followed by stem cell transplantation from a matched unrelated donor or a partially matched related donor.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 4 Weeks to 50 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •acute leukemia
- •chronic leukemia
- •lymphoblastic lymphoma
Exclusion Criteria
- •organ dysfunction
- •HIV positive
Outcomes
Primary Outcomes
oxicity and efficacy of TBI and cyclophosphamide as preparation for hematopoietic cell transplantation from partially matched and unrelated donors.
Secondary Outcomes
- Overall Survival
- Event Free Survival
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Unknown
Not Applicable
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic DisordersChediak-Higashi SyndromeGraft Versus Host DiseaseX-Linked Lymphoproliferative SyndromeFamilial Erythrophagocytic LymphohistiocytosisVirus-Associated Hemophagocytic SyndromeHemophagocytic LymphohistiocytosisNCT00006056Fairview University Medical Center40
Terminated
Phase 2
Unrelated Donor Transplant for Malignant and Non-Malignant DisordersLymphomaLeukemiaBone Marrow Failure SyndromesImmunodeficienciesHistiocytosisNCT01050439Columbia University22
Completed
Not Applicable
Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem CellsHEMATOLOGIC MALIGNANCIESNCT00770523Cooperative Study Group A for Hematology52
Recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cellsMDS (Myelodysplastic Syndrome)Severe Aplastic AnemiaNCT01174108National Heart, Lung, and Blood Institute (NHLBI)120
Terminated
Phase 2
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerChronic Myeloproliferative DisordersMultiple Myeloma and Plasma Cell NeoplasmLymphomaLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnusual Cancers of ChildhoodNCT00281879OHSU Knight Cancer Institute200